CAI Caris Life Sciences, Inc.

In general, many current shareholders have lived through a deep correction that started after Caris Life Sciences peaked at 42.50 on Aug. 22 last year. Thus, Caris Life Sciences is still extended. Caris Life Sciences uses artificial intelligence and other technology to profile molecules of interest to the life sciences industry.

Key TakeawaysSector Rally: Caris Life Sciences (CAI) stock jumped 9. 61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.

Caris Life Sciences, Inc. (CAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Caris Life Sciences (CAI) is drawing fresh attention after announcing that its researchers will present seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul this month. For investors, the World Conference presentations and August’s pancreatic cancer AI publication land against a mixed share price backdrop for Caris Life Sciences, with the stock down 28.06% on a 1 year total shareholder return basis but showing strong 90 day share price momentum of 55.33% and a 30 day...

Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lung cancer care. Caris also published a validated AI driven method designed to help optimize first line pancreatic cancer treatment choices. For readers following how AI is reshaping cancer research and treatment, it can also be useful to look at other...

After soaring by as much as 21.58 percent on Thursday, Caris Life Sciences Inc. (NASDAQ:CAI) heads into the next trading session with investors focused less on a stellar earnings performance and more on whether it can sustain its momentum towards a recovery. To recall, the company reported strong earnings results in the second quarter of […]

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

Moby summary of Caris Life Sciences, Inc.'s Q2 2026 earnings call

Caris Life Sciences Inc (CAI) reports 45% revenue growth and raises full-year guidance amid strong molecular profiling performance and strategic product launches.

Caris Life Sciences (NASDAQ:CAI) reported record clinical volume and raised its full-year revenue outlook after second-quarter revenue increased 45% from a year earlier, driven by growth in molecular profiling services, higher average selling prices and an expanding commercial organization. The com

Caris Life Sciences,?Inc. (CAI) delivered earnings and revenue surprises of +100.00% and +14.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CareDx (CDNA) delivered earnings and revenue surprises of +68.18% and +15.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Caris Life Sciences stock has had a tough run over the past year, yet the valuation checks still lean in its favor, creating a gap between weak recent returns and what the broader metrics suggest about pricing. Over the past 12 months, Caris Life Sciences has fallen 47.3%, which raises the question of whether sentiment has swung too far relative to fundamentals. New products like the Caris Detect multi cancer screening test and the in house PTEN IHC testing may support expectations for...

Caris Life Sciences (CAI) recently announced plans to report second quarter 2026 results on August 5. This will give investors a fresh look at its finances shortly after launching in-house PTEN IHC testing. See our latest analysis for Caris Life Sciences. Despite the new PTEN IHC offering and the upcoming earnings release, momentum in Caris Life Sciences' stock has been weak, with the share price falling 22.1% over three months and the 1-year total shareholder return declining 47.3%. This...

Caris Life Sciences, NasdaqGS:CAI, has introduced in-house PTEN immunohistochemistry testing. The launch follows FDA approval of a biomarker guided therapy for PTEN deficient metastatic prostate cancer. The new PTEN IHC service is integrated into Caris' existing molecular profiling platform. For investors watching precision oncology, Caris Life Sciences, NasdaqGS:CAI, sits at the intersection of diagnostics and targeted treatment selection. The new PTEN IHC capability fits into the...